Cargando…

Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer

SIMPLE SUMMARY: ER+ breast cancer is the most diagnosed subtype and patient prognosis has improved in recent years thanks largely to the development of endocrine-targeting therapies including tamoxifen. Unfortunately, many tumors will recur as endocrine-therapy-resistant metastases. Therefore, in or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zboril, Emily K., Grible, Jacqueline M., Boyd, David C., Hairr, Nicole S., Leftwich, Tess J., Esquivel, Madelyn F., Duong, Alex K., Turner, Scott A., Ferreira-Gonzalez, Andrea, Olex, Amy L., Sartorius, Carol A., Dozmorov, Mikhail G., Harrell, J. Chuck
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296623/ https://www.ncbi.nlm.nih.gov/pubmed/37370789 http://dx.doi.org/10.3390/cancers15123179

Ejemplares similares

Discovering Synergistic Compounds with BYL-719 in PI3K Overactivated Basal-like PDXs
por: Boyd, David C., et al.
Publicado: (2023)

Identification of nuclear export inhibitor-based combination therapies in preclinical models of triple-negative breast cancer
por: Rashid, Narmeen S., et al.
Publicado: (2021)

Transcriptomic changes underlying EGFR inhibitor resistance in human and mouse models of basal-like breast cancer
por: Rashid, Narmeen S., et al.
Publicado: (2022)

Serine residues 726 and 780 have nonredundant roles regulating STAT5a activity in luminal breast cancer
por: Woock, Alicia E., et al.
Publicado: (2021)

Separation of breast cancer and organ microenvironment transcriptomes in metastases
por: Alzubi, Mohammad A., et al.
Publicado: (2019)

The human intermediate prolactin receptor is a mammary proto-oncogene
por: Grible, Jacqueline M., et al.
Publicado: (2021)

Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer
por: Liu, Ying, et al.
Publicado: (2020)

Rewiring of the 3D genome during acquisition of carboplatin resistance in a triple-negative breast cancer patient-derived xenograft
por: Dozmorov, Mikhail G., et al.
Publicado: (2023)

Publisher Correction: Rewiring of the 3D genome during acquisition of carboplatin resistance in a triple-negative breast cancer patient-derived xenograft
por: Dozmorov, Mikhail G., et al.
Publicado: (2023)

Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer [Corrigendum]
Publicado: (2022)

Identification of synergistic drug combinations using breast cancer patient-derived xenografts
por: Turner, Tia H., et al.
Publicado: (2020)

SAT-130 The Intermediate Prolactin Receptor Is a Breast Cancer Oncogene
por: Grible, Jacqueline M, et al.
Publicado: (2020)

Tamoxifen Action in ER-Negative Breast Cancer
por: Manna, Subrata, et al.
Publicado: (2016)

SAT-139 STAT5A Regulation by Serine Phosphorylation in Breast Cancer
por: Woock, Alicia E, et al.
Publicado: (2020)

Tamoxifen-Independent Recombination in the RIP-CreER Mouse
por: Liu, Yanmei, et al.
Publicado: (2010)

Analysis of The Cancer Genome Atlas sequencing data reveals novel properties of the human papillomavirus 16 genome in head and neck squamous cell carcinoma
por: Nulton, Tara J., et al.
Publicado: (2017)

Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis
por: Esserman, Laura J, et al.
Publicado: (2005)

Evaluation of the NRF1-proteasome axis as a therapeutic target in breast cancer
por: Byers, Holly A., et al.
Publicado: (2023)

Tamoxifen induces hypercoagulation and alterations in ERα and ERβ dependent on breast cancer sub-phenotype ex vivo
por: Pather, K., et al.
Publicado: (2020)

Tamoxifen-independent Cre-activity in SMMHC-CreER(T2) mice
por: Steffensen, L.B., et al.
Publicado: (2022)

Synergistic Effects of Lauryl Gallate and Tamoxifen on Human Breast Cancer Cell
por: GHATREH SAMANI, Keihan, et al.
Publicado: (2020)

Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ
por: Mishra, Ameet K., et al.
Publicado: (2016)

The combination of methylsulfonylmethane and tamoxifen inhibits the Jak2/STAT5b pathway and synergistically inhibits tumor growth and metastasis in ER-positive breast cancer xenografts
por: SP, Nipin, et al.
Publicado: (2015)

CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance
por: Gao, Tian, et al.
Publicado: (2014)

Effects of Jaeumkanghwa-tang on tamoxifen responsiveness in preclinical ER+ breast cancer model
por: De Oliveira Andrade, Fabia, et al.
Publicado: (2019)

Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast Cancer
por: Tsoi, Ho, et al.
Publicado: (2022)

The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans
por: Hai, Trieu Phan, et al.
Publicado: (2019)

FGFR1 Is Associated With Tamoxifen Resistance and Poor Prognosis of ER-Positive Breast Cancers by Suppressing ER Protein Expression
por: Lv, Qing, et al.
Publicado: (2021)

excluderanges: exclusion sets for T2T-CHM13, GRCm39, and other genome assemblies
por: Ogata, Jonathan D, et al.
Publicado: (2023)

The Synergistic Effects of Celastrol in combination with Tamoxifen on Apoptosis and Autophagy in MCF-7 Cells
por: Wang, Lijun, et al.
Publicado: (2021)

Disruption of the ER-α36-EGFR/HER2 Positive Regulatory Loops Restores Tamoxifen Sensitivity in Tamoxifen Resistance Breast Cancer Cells
por: Yin, Li, et al.
Publicado: (2014)

Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma
por: Ma, Ji, et al.
Publicado: (2014)

Effects of CreER(T2), 4-OH Tamoxifen, and Gender on CFU-F Assays
por: McHaffie, Sophie L., et al.
Publicado: (2016)

LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer
por: Xue, Xingyang, et al.
Publicado: (2015)

Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer
por: Menendez, Javier A., et al.
Publicado: (2021)

Limitations of Tamoxifen Application for In Vivo Genome Editing Using Cre/ER(T2) System
por: Ilchuk, Leonid A., et al.
Publicado: (2022)

Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα (+) breast cancer
por: Poulard, Coralie, et al.
Publicado: (2023)

A retrospective cohort study of tamoxifen versus surgical treatment for ER-positive gynecomastia
por: He, Weili, et al.
Publicado: (2023)

Modulation of transforming growth factor beta expression and induction of apoptosis by tamoxifen in ER positive and ER negative breast cancer cells.
por: Benson, J. R., et al.
Publicado: (1996)

The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer
por: Liu, Shu-Shu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rklq3gea9k9l1gk4vj009mgta5